REACH14 Dec 2021 07:18
Confirmation of detection of Omicron variant
OMEGA DIAGNOSTICS GROUP PLC
Released 07:00:11 14 December 2021
RNS Number : 5063V
Omega Diagnostics Group PLC
14 December 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Confirmation of detection of Omicron variant
VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd ("Mologic") that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.
This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.
Colin King, CEO, Omega Diagnostics, said: "We are very pleased be in a position to confirm that the VISITECT® COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use."